Your team at a sponsoring pharmaceutical company recently published a clinical study in a reputable journal. Soon after, a healthcare professional shared a summary generated by an AI-powered medical tool that appears to overstate the study’s efficacy and underrepresent key limitations. The AI summary is gaining traction in online discussions.
While the original published abstract is accurate, you recognize that its structure may make it easier for AI tools to generate simplified, and potentially misleading, interpretations. Now, there is internal debate about whether your team has any responsibility to respond. Some colleagues argue that once the manuscript is published, interpretation by third-party tools is out of the authors’ or the company’s control. Others believe there is a professional obligation to step in when summaries derived from a company-sponsored publication could influence clinical understanding. As a publications lead, you are asked how to proceed.
What Would You Do?
A. Take no direct action—trust that the full publication provides appropriate context and that third-party summaries are outside your responsibility.
B. Work closely with the lead author and the senior, corresponding author to issue a clarification (e.g., via company channels, author commentary, or correspondence) to reinforce accurate interpretation of the findings.
C. After consulting with the lead and senior authors, engage with the AI tool or platform provider to flag the issue and explore whether corrections or refinements can be made.
D. Use this as a learning opportunity to adjust future publication practices, but do not intervene retroactively for this instance.
This poll is now closed as of May 1, 2026. Results are expected to be published in June.
